Literature DB >> 33977086

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Masatoshi Kudo1.   

Abstract

Entities:  

Keywords:  Atezolizumab plus bevacizumab; Hepatocellular carcinoma; Lenvatinib; Ramucirumab; Regorafenib

Year:  2021        PMID： 33977086      PMCID： PMC8077462          DOI： 10.1159/000514312

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  51 in total

1.  Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.

Authors:  Shao-Lai Zhou; Zheng-Jun Zhou; Zhi-Qiang Hu; Xiao-Wu Huang; Zheng Wang; Er-Bao Chen; Jia Fan; Ya Cao; Zhi Dai; Jian Zhou
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

2.  Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.

Authors:  Ying Zhu; Jing Yang; Da Xu; Xiao-Mei Gao; Ze Zhang; Jennifer L Hsu; Chia-Wei Li; Seung-Oe Lim; Yuan-Yuan Sheng; Yu Zhang; Jian-Hua Li; Qin Luo; Yan Zheng; Yue Zhao; Lu Lu; Hu-Liang Jia; Mien-Chie Hung; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Gut       Date:  2019-03-22       Impact factor: 23.059

3.  Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

Authors:  Mengde Cao; Yiling Xu; Je-in Youn; Roniel Cabrera; Xiaokui Zhang; Dmitry Gabrilovich; David R Nelson; Chen Liu
Journal:  Lab Invest       Date:  2011-02-14       Impact factor: 5.662

4.  Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Authors:  Osamu Tohyama; Junji Matsui; Kotaro Kodama; Naoko Hata-Sugi; Takayuki Kimura; Kiyoshi Okamoto; Yukinori Minoshima; Masao Iwata; Yasuhiro Funahashi
Journal:  J Thyroid Res       Date:  2014-09-10

5.  A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.

Authors:  Wenbo Yao; Qian Ba; Xiaoguang Li; Huiliang Li; Shoude Zhang; Ya Yuan; Feng Wang; Xiaohua Duan; Jingquan Li; Weidong Zhang; Hui Wang
Journal:  EBioMedicine       Date:  2017-07-18       Impact factor: 8.143

6.  Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Authors:  Yasmin A Lyons; Sunila Pradeep; Sherry Y Wu; Monika Haemmerle; Jean M Hansen; Michael J Wagner; Alejandro Villar-Prados; Archana S Nagaraja; Robert L Dood; Rebecca A Previs; Wei Hu; Yang Zhao; Duncan H Mak; Zhilan Xiao; Brenda D Melendez; Gregory A Lizee; Imelda Mercado-Uribe; Keith A Baggerly; Patrick Hwu; Jinsong Liu; Willem W Overwijk; Robert L Coleman; Anil K Sood
Journal:  Oncotarget       Date:  2017-08-24

7.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Authors:  Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; Subhiksha Nandakumar; Joshua Armenia; Danny N Khalil; Melanie Albano; Michele Ly; Jinru Shia; Jaclyn F Hechtman; Ritika Kundra; Imane El Dika; Richard K Do; Yichao Sun; T Peter Kingham; Michael I D'Angelica; Michael F Berger; David M Hyman; William Jarnagin; David S Klimstra; Yelena Y Janjigian; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-29       Impact factor: 12.531

8.  PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.

Authors:  Wing Lam; Zaoli Jiang; Fulan Guan; Xiu Huang; Rong Hu; Jing Wang; Scott Bussom; Shwu-Huey Liu; Hongyu Zhao; Yun Yen; Yung-Chi Cheng
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.996

9.  Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.

Authors:  Akio Osa; Takeshi Uenami; Shohei Koyama; Kosuke Fujimoto; Daisuke Okuzaki; Takayuki Takimoto; Haruhiko Hirata; Yukihiro Yano; Soichiro Yokota; Yuhei Kinehara; Yujiro Naito; Tomoyuki Otsuka; Masaki Kanazu; Muneyoshi Kuroyama; Masanari Hamaguchi; Taro Koba; Yu Futami; Mikako Ishijima; Yasuhiko Suga; Yuki Akazawa; Hirotomo Machiyama; Kota Iwahori; Hyota Takamatsu; Izumi Nagatomo; Yoshito Takeda; Hiroshi Kida; Esra A Akbay; Peter S Hammerman; Kwok-Kin Wong; Glenn Dranoff; Masahide Mori; Takashi Kijima; Atsushi Kumanogoh
Journal:  JCI Insight       Date:  2018-10-04
View more
  9 in total

Review 1.  Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Authors:  Hui-Chuan Sun; Jian Zhou; Zheng Wang; Xiufeng Liu; Qing Xie; Weidong Jia; Ming Zhao; Xinyu Bi; Gong Li; Xueli Bai; Yuan Ji; Li Xu; Xiao-Dong Zhu; Dousheng Bai; Yajin Chen; Yongjun Chen; Chaoliu Dai; Rongping Guo; Wenzhi Guo; Chunyi Hao; Tao Huang; Zhiyong Huang; Deyu Li; Gang Li; Tao Li; Xiangcheng Li; Guangming Li; Xiao Liang; Jingfeng Liu; Fubao Liu; Shichun Lu; Zheng Lu; Weifu Lv; Yilei Mao; Guoliang Shao; Yinghong Shi; Tianqiang Song; Guang Tan; Yunqiang Tang; Kaishan Tao; Chidan Wan; Guangyi Wang; Lu Wang; Shunxiang Wang; Tianfu Wen; Baocai Xing; Bangde Xiang; Sheng Yan; Dinghua Yang; Guowen Yin; Tao Yin; Zhenyu Yin; Zhengping Yu; Bixiang Zhang; Jialin Zhang; Shuijun Zhang; Ti Zhang; Yamin Zhang; Yubao Zhang; Aibin Zhang; Haitao Zhao; Ledu Zhou; Wu Zhang; Zhenyu Zhu; Shukui Qin; Feng Shen; Xiujun Cai; Gaojun Teng; Jianqiang Cai; Minshan Chen; Qiang Li; Lianxin Liu; Weilin Wang; Tingbo Liang; Jiahong Dong; Xiaoping Chen; Xuehao Wang; Shusen Zheng; Jia Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

2.  Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.

Authors:  Osman Öcal; Kerstin Schütte; Christoph J Zech; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Chris Verslype; Bernhard Gebauer; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alexander Philipp; Thomas Berg; Heinz J Klümpen; Julia Benckert; Maciej Pech; Antonio Gasbarrini; Holger Amthauer; Peter Bartenstein; Bruno Sangro; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-02       Impact factor: 10.057

3.  Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giovanni Brandi
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 12.430

4.  Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Masaru Matsumura; Satoshi Okubo; Nozomu Muraishi; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2022-03-01       Impact factor: 3.734

5.  Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.

Authors:  Shigeki Yano; Tomokazu Kawaoka; Yusuke Johira; Ryoichi Miura; Masanari Kosaka; Yuki Shirane; Serami Murakami; Kei Amioka; Kensuke Naruto; Yuwa Ando; Yumi Kosaka; Kenji Yamaoka; Kenichiro Kodama; Shinsuke Uchikawa; Hatsue Fujino; Atsushi Ohno; Takashi Nakahara; Eisuke Murakami; Wataru Okamoto; Masami Yamauchi; Michio Imamura; Keiichi Mori; Kouji Arihiro; Shintaro Kuroda; Tsuyoshi Kobayashi; Hideki Ohdan; Hiroshi Aikata
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

6.  Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air.

Authors:  Vikrant Rai; Sandeep Mukherjee
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

Review 7.  Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.

Authors:  Thomas Yau; David Tai; Stephen Lam Chan; Yi-Hsiang Huang; Su Pin Choo; Chiun Hsu; Tan To Cheung; Shi-Ming Lin; Wei Peng Yong; Joycelyn Lee; Thomas Leung; Tracy Shum; Cynthia S Y Yeung; Anna Yin-Ping Tai; Ada Lai Yau Law; Ann-Lii Cheng; Li-Tzong Chen
Journal:  Liver Cancer       Date:  2022-06-17       Impact factor: 12.430

Review 8.  Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.

Authors:  Marie Decraecker; Caroline Toulouse; Jean-Frédéric Blanc
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

9.  BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.

Authors:  Stephanie Busche; Katharina John; Franziska Wandrer; Florian W R Vondran; Ulrich Lehmann; Heiner Wedemeyer; Frank Essmann; Klaus Schulze-Osthoff; Heike Bantel
Journal:  Cell Death Dis       Date:  2021-07-26       Impact factor: 8.469
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.